6 June 2019
Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia…
Aviva plc investor update…
Portfolio Update
5 June 2019
Trading statement and deferral of preference dividend…
Results for the 52 weeks ended 29 March 2019…
£30m Commitment from Irish Sovereign Wealth Investor…
Full Year Results, NAV & Dividend Declaration…
4 June 2019
Management Day 2019: Shell, strongly positioned for the future of energy, provides strategy update and financial outlook to 2025 …